Hioscina

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hioscina

This section provides a foundational understanding of the medicine Hioscina, focusing on its identity, composition, and general purpose as an antispasmodic agent.

Property Description
Active ingredient Hyoscine Butylbromide (Scopolamine Butylbromide)
Form Oral tablets, solution for injection (parenteral)
Pharmacological class Anticholinergic agent, Antispasmodic
Common use Relief of smooth muscle spasms or cramping
Origin Semisynthetic derivative of Hyoscine alkaloid

What Type of Medicine is Hioscina (Hyoscine Butylbromide)?

Hioscina is a potent Antispasmodic agent belonging to the Anticholinergic class of medications. Its active ingredient is Hyoscine Butylbromide (HBB), which is a single-ingredient product derived as a semisynthetic derivative of the natural Tropane alkaloid, Hyoscine.


The drug entity is chemically engineered as a quaternary ammonium compound, a structural feature that ensures it is a highly peripherally acting substance. This characteristic prevents it from readily crossing into the central nervous system, keeping its mechanism of action focused on the body's organs. Hyoscine Butylbromide is included on the Model List of Essential Medicines in its injectable parenteral formulation, affirming its global healthcare importance.

Composition and Forms: Peripherally Acting Derivative

Hyoscine Butylbromide is provided in several dosage form(s) to facilitate a flexible route of administration. These include oral formulations like tablets and injectable parenteral formulations—a sterile solution for injection.


This formulation permits both oral use and, for acute situations, rapid administration via intramuscular, subcutaneous, or intravenous routes. The drug's essential function is to act as a spasmolytic drug by blocking the effects of the neurotransmitter acetylcholine at specific Muscarinic receptors on the smooth muscle fibers. By preventing these signals, it stops the involuntary, painful spasms or cramping.

The General Purpose of This Antispasmodic Agent

The general purpose of Hioscina is the focused, rapid alleviation of acute discomfort originating from muscular spasms in the body's visceral organs, providing a powerful, targeted spasmolytic benefit. This makes it a standard therapeutic choice in scenarios involving acute cramping of the gastrointestinal or genitourinary tracts.

Regulatory References

  1. World Health Organization (WHO)
  2. WHO Essential Medicines List

What side effects are possible with Hioscina?

Possible Side Effects and Safety Information

The safety profile of Hioscina (Hyoscine Butylbromide) is defined by its action as a peripherally acting anticholinergic agent, with adverse reactions categorized by frequency and the body system affected, as documented in regulatory labeling.

Frequency-Classified Adverse Reactions

The most commonly reported effects stem from the medicine's anticholinergic properties. These are categorized in official documents:

Classification Examples of Reactions
Uncommon Tachycardia (increased heart rate), Dry mouth, Urticaria (hives) or Rash, Dyshidrosis (abnormal sweating).
Rare Urinary retention (difficulty passing urine).
Not Known Anaphylactic shock, Dyspnoea (shortness of breath), Hypotension (decreased blood pressure), Mydriasis, Increased intraocular pressure, Accommodation disorders (transient blurred vision).

Serious Adverse Reactions and Safety Constraints

The regulatory profile highlights the potential for serious, immediate reactions, particularly following the injectable form. These include anaphylactic shock (which can be fatal) and clinically significant hypotension and severe tachycardia, especially in individuals with pre-existing cardiac conditions.

The medicine is contraindicated in specific conditions, which are structural or pressure-related, including untreated narrow-angle glaucoma, certain gastrointestinal obstructions such as paralytic or obstructive ileus, and prostatic hypertrophy with urinary retention. Use requires caution in populations such as older adults, who may be more susceptible to side effects like urinary retention.

Overdose and Emergency Response

Hyoscine Butylbromide is a peripherally acting anticholinergic agent, and overdosage may manifest primarily with signs of excessive anticholinergic activity. The documented clinical presentation typically includes tachycardia (rapid heart rate), dry mouth, reddening of the skin, and difficulty passing urine (urinary retention), often accompanied by transient visual disturbances.

In instances of severe intoxication, regulatory documents note the potential for life-threatening complications affecting the cardiovascular and respiratory systems. These serious outcomes can include circulatory failure and respiratory paralysis, with some reports also noting central nervous system effects such as confusion, seizures, and progression to coma.

Due to the risk of severe systemic collapse, the official labeling mandates that individuals seek immediate medical attention for a suspected overdosage. Urgent medical care is required if severe symptoms persist or if signs of respiratory or circulatory distress occur. Supportive management is crucial, which may include procedures like gastric lavage or administration of activated charcoal for oral overdose, as well as specialized medical interventions such as intubation for respiratory failure or catheterisation for urinary retention. The official documents state that overdosage symptoms generally respond to the administration of parasympathomimetics.

Therapeutic Uses of Hioscina

Quick Facts

  • Targeted relief: Associated with abdominal and gastrointestinal discomfort.
  • Conditions addressed: Helps manage painful cramping and spasms in the stomach, intestines, and urinary tract.
  • Context of use: Indicated for symptomatic management of conditions such as Irritable Bowel Syndrome (IBS), biliary colic, and renal colic.

What Hioscina Treats: Main Uses and Benefits

Hioscina, also known as hyoscine butylbromide, is utilized in medical practice to provide relief from painful muscle spasms and cramping within the abdomen and urogenital system. It is specifically indicated for the symptomatic management of discomfort associated with various conditions.

Medical practitioners may use this agent to address painful spasms arising in the stomach and intestines, a common symptom in conditions like irritable bowel syndrome (IBS). Furthermore, Hioscina is used for discomfort related to spasms in the bile ducts (biliary colic) and the urinary system (renal colic).

The medication's benefit is in its ability to contribute to the relaxation of the involuntary smooth muscles in the gastrointestinal and urinary tracts, offering support for individuals experiencing these specific types of visceral pain. Use is generally recommended for short-term, symptomatic relief under the guidance of a healthcare professional.

Eligibility and Restrictions for Use

Hioscina (hyoscine butylbromide) is a spasmolytic agent used to relieve cramps and spasms of the gastrointestinal and genitourinary tracts. It is generally suitable for most adults and children over the age of six, but its use requires medical consultation, particularly for certain brands or formulations (such as those for Irritable Bowel Syndrome, which require a prior medical diagnosis).

However, Hioscina is contraindicated in patients with specific medical conditions due to the risk of exacerbating these issues. Patients should not take this medication if they have:

  • Myasthenia gravis: A condition causing muscle weakness.
  • Glaucoma (especially narrow-angle): A condition involving increased pressure in the eye.
  • Megacolon or Bowel Blockages: Conditions such as paralytic or obstructive ileus, where the bowel is severely enlarged or blocked and not working properly.
  • Hypersensitivity or Allergy: Known allergy to hyoscine butylbromide or any of its components.

Caution is also advised in patients with an enlarged prostate (which may cause urinary retention), certain heart conditions (like a very fast heart rate or irregular rhythm), or those who are pregnant or breastfeeding. Children under six years old should generally not use this medication. Always discuss your full medical history with a healthcare professional before starting treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Hioscina (Hyoscine Butylbromide) primarily through pharmacodynamic effects and administration restrictions.

Documented Interaction Patterns

The co-administration of Hioscina with certain medicines may lead to an intensification or diminution of effects, as explicitly stated in government labeling.

Interacting Substance/Class Official Interaction Statement
Other Anticholinergic Agents The anticholinergic effects of the combined medicines may be intensified (additive effect). This includes agents such as tricyclic antidepressants and specific antihistamines.
Dopamine Antagonists (e.g., Metoclopramide) Results in the diminution of the effects of both medicines on the gastrointestinal tract due to functional antagonism.
Antacids or Adsorbent Antidiarrheals May reduce the oral absorption of Hioscina, which can decrease its therapeutic effectiveness. Regulatory guidance suggests separating administration times.
Beta-adrenergic Agents May result in the enhancement of tachycardic effects.

Administration and Substance Restrictions

Official prescribing information includes a specific route-based contraindication involving the parenteral formulation. The use of Hioscina by intramuscular injection is strictly contraindicated in patients receiving concomitant anticoagulant drugs, due to the risk of localized intramuscular haematoma. Furthermore, regulatory labels advise that co-administration with alcohol may enhance specific effects, such as drowsiness, leading to a caution against concurrent use.

Mechanism of Action

The drug, Hioscina (scopolamine), functions as an antimuscarinic agent. Its action is primarily exerted through the cholinergic system, resulting in diminished smooth muscle contraction and decreased glandular secretion.

Antagonizing Muscarinic Acetylcholine Receptors

Hioscina acts as a competitive antagonist at peripheral muscarinic acetylcholine receptors (mAChRs), particularly M1 and M2 subtypes found in smooth muscle and exocrine glands. By binding to these receptors, it blocks the binding and action of the neurotransmitter acetylcholine. This inhibition of cholinergic signaling is the fundamental mechanism that governs its downstream physiological effects, enabling adjustment of pathways governing involuntary physiological processes.

Modification of Smooth Muscle Contractile Activity

The blockade of mAChRs in smooth muscle tissues induces a decrease in contractile activity. This mechanism involves the suppression of the signaling cascade that promotes heightened smooth muscle motor activity. The resulting physiological effect modifies the output of systems characterized by heightened involuntary muscular activity.

Influence on Exocrine Gland Secretory Output

Hioscina influences the mechanisms controlling glandular secretory output by blocking cholinergic stimulation of exocrine glands, such as salivary, sweat, and bronchial glands. This antisecretory effect helps limit the molecular signaling by acetylcholine on glandular function, inducing an observable shift in glandular output.

Dosage and Administration Information

How Hioscina is Used: Administration Guidelines

Hioscina (Hyoscine Butylbromide) is administered through two routes: oral tablets (10 mg strength) and a parenteral solution (20 mg/ mL strength) for injection, providing flexibility for varying contexts of use.

Oral Administration

For adult use, the standard oral dose ranges from 10 mg to 20 mg per administration, which may be repeated up to four times daily. The tablets must be swallowed whole with water and may be taken independent of food. For the pediatric population aged 6 to 11 years, the standard dose is 10 mg taken three times daily. Use is designated strictly for short-term, symptomatic relief, and treatment should generally not exceed 2 weeks without professional medical review of the cause of the pain.

Parenteral Administration

The injectable solution is administered via intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes for acute situations. The usual single dose is 20 mg and may be repeated after 30 minutes if required, with a maximum daily limit of 100 mg. IV injection must be performed as a slow administration. Furthermore, a specific procedural constraint requires the avoidance of the intramuscular route in patients receiving anticoagulant drugs; in such cases, the IV or SC routes should be used instead. No dedicated dose adjustments for older patients are typically included.

Recent Clinical Evidence

Research evidence / Overview of studies for Hioscina

Evidence for Acute Abdominal Cramping and Spasm

Research has examined Hioscina in the context of conditions characterized by fluctuating or episodic manifestations such as sudden cramps or spasms in the abdominal area. The research design primarily involves short-term, randomized controlled trials (RCTs) and comparative effectiveness trials, which explored Hioscina against a neutral substance (placebo) or against other comparators used for pain relief. These studies mainly included adults and some pediatric cohorts (children aged 6 and older) presenting with acute discomfort.

The outcomes related to physical discomfort was monitored closely in these trials. Researchers used in research exploring how symptoms change over time to track pain intensity scores, measure the time recorded until the initial outcomes describing episodic or acute changes were assessed, and determine the requirement for supplementary, or rescue, pain medication. Studies reported measurements of pain intensity change across several RCTs and comparative studies involving adults and children. What remains uncertain for this general indication is the long-term characterization of outcomes reflecting daily functioning or activity level after the acute episode has passed, as the follow-up durations were limited.


Evidence for Irritable Bowel Syndrome (IBS) Symptoms

Hioscina was studied for its potential role in outcomes related to physical discomfort such as abdominal pain associated with Irritable Bowel Syndrome (IBS). The research base here relies heavily on systematic reviews and meta-analyses that pooled data from many smaller randomized controlled trials. These trials applied in studies examining patient-reported experiences to gauge global symptom relief and the frequency of abdominal pain.

Research described how symptoms were measured and recorded in the observed populations over periods usually lasting between four and six weeks. However, the evidence quality varies across studies and certainty remains low for this indication. Many of the trials are older, meaning they did not use the standardized diagnostic criteria for IBS that are used today. Due to this factor and the modest sample sizes in many of the individual studies, subgroup findings are uncertain, and findings were mixed across various reviews regarding the consistency of the observed patterns.


Evidence Gaps and Areas of Uncertainty

A significant research limitation is that evidence quality varies across studies. Data are still emerging regarding definitive comparisons against all modern spasmolytic and analgesic alternatives. Additionally, the subgroup findings are uncertain, suggesting limited information about the consistency of observed patterns among patients with different levels of symptom severity or different comorbidities. Overall, the research highlights what is known — and what is still uncertain—and indicates that research is ongoing to provide clearer context.

Key Studies & References

  1. Hyoscine butylbromide - eEML - Electronic Essential Medicines List
  2. A Comprehensive Review of the Effects of Hyoscine Butylbromide in Childhood

Frequently Asked Questions (FAQ)

Common questions about Hioscina (FAQ)

Q: Is Hioscina the same as Hyoscine?

No. The active ingredient in the medicine is called Hyoscine Butylbromide, which is a chemical derivative of the natural substance Hyoscine (also known as Scopolamine).

Hioscina has been chemically engineered to be a peripherally acting drug, meaning it primarily affects organs outside of the central nervous system.


Q: Are there different brand names for the drug Hioscina?

Yes, the drug Hioscina (Hyoscine Butylbromide) is marketed globally under various brand names. The most recognized of these international brand names is Buscopan.


Q: What should I know about taking Hioscina if I am elderly?

Official labeling advises caution when the medicine is used by older adults. They may be more susceptible to the drug’s anticholinergic side effects, such as urinary retention (difficulty passing urine).

Official guidance suggests that these individuals should be closely monitored for adverse effects.


Q: Can children or adolescents use Hioscina?

The oral tablets are typically labeled for use in children aged 6 to 11 years with a dose specified in the official documents.

For children under 6 years old, as well as for adolescents, the use of Hioscina should be determined by a healthcare professional based on individual need.


Q: What is the pregnancy category or classification for Hioscina?

Hioscina is generally classified as Pregnancy Category C by the FDA. This classification means that while animal studies have shown potential adverse effects on a fetus, there are no adequate studies available in human pregnancy.

Prescribing information indicates that its use should be reserved for situations where the potential benefit justifies the potential risk.


Q: What has medical research revealed about Hioscina’s long-term use?

Official administration guidelines designate the oral form for short-term, symptomatic relief. Official guidelines generally recommend that treatment should not exceed two weeks without a medical review of the underlying condition causing the discomfort.

Research studies for this indication often have limited follow-up durations.


Q: How quickly does Hioscina start working after taking it?

According to official pharmacokinetic information, following oral administration, the onset of therapeutic effects is generally rapid. This onset is typically expected to begin within 15 to 30 minutes after the dose is taken.


Q: How long do the effects of Hioscina usually last?

Factual information indicates that the drug’s elimination half-life from the bloodstream is approximately six hours. This figure is used by regulators to define the expected duration of the medicine's activity in the body.


Q: Is Hioscina available over the counter in some countries?

The legal status of Hioscina varies globally based on national regulation. While it remains a prescription-only medicine in some regions, it is available for purchase over-the-counter in many countries.


Q: Is Hioscina considered a controlled substance?

Hioscina is not classified as a controlled substance by major governmental bodies overseeing drug scheduling. Its legal status is varied globally, being available as an over-the-counter medicine in many countries while remaining prescription-only in others.


Q: Does Hioscina affect the central nervous system?

Hioscina is specifically defined as a peripherally acting anticholinergic agent in official documents.

Its chemical structure is designed to limit its ability to readily cross the blood-brain barrier, thereby minimizing effects on the central nervous system.


Q: Is Hioscina ever used for issues related to motion sickness?

No. Official regulatory indications for Hioscina (Hyoscine Butylbromide) are restricted to the treatment of smooth muscle spasms in the gastrointestinal or genitourinary tract. It is not labeled or approved for the treatment or prevention of motion sickness.


Q: What happens if a dose of Hioscina is missed?

Patient information generally advises that if a dose is remembered, it should be taken right away. However, if it is already nearly time for your next scheduled dose, regulatory guidance suggests skipping the missed dose and continuing with the regular schedule. It is important not to take a double dose to make up for the missed one.


Q: Are there specific instructions for stopping Hioscina?

Official patient information advises consulting a healthcare professional if symptoms change, worsen, or have not improved after two weeks of use. This time period is the standard regulatory signal for a medical review and potential cessation of the drug.


Q: Can Hioscina cause dry mouth, and is that a sign it is working?

Dry mouth is listed in official documents as an uncommon side effect due to the drug’s anticholinergic properties. However, regulatory information does not state that this specific side effect is an indicator that the medicine has begun working effectively.


Q: Is it normal to feel a change in bowel movements when taking Hioscina?

Hioscina's primary mechanism of action is to relax the smooth muscles of the digestive tract, which can reduce gut movement. This mechanism may lead to a change in bowel movements, such as constipation, which is often listed as a common anticholinergic side effect.


Q: Is it possible to become dependent on Hioscina?

Official regulatory documentation does not list drug dependence or abuse potential as a recognized risk or reported side effect of Hioscina.


Q: Are there any known drug-herb interactions with Hioscina?

Official drug information advises caution regarding the use of certain herbal remedies. This is especially true for those that may increase anticholinergic side effects such as sleepiness, dry mouth, or difficulty passing urine.


Q: Are there special considerations for taking Hioscina if I have kidney or liver issues?

Official prescribing information advises that caution is warranted in patients who have impaired liver or kidney function. Consultation with a healthcare professional is necessary to determine appropriateness if you have a history of impaired kidney or liver function.


Q: Are there any specific foods or drinks that should be avoided with Hioscina?

Regulatory information advises caution regarding the concurrent use of alcohol, as it may intensify certain effects like drowsiness. Official documents do not typically note specific interactions with food, meaning the medicine can generally be taken independent of meals.


Q: Does Hioscina cause drowsiness, and if so, how common is it?

Official labeling does not typically list drowsiness as a common side effect in its frequency classifications, but related effects like dizziness have been reported. Drowsiness is noted as a potential symptom of overdose and may be enhanced if the medicine is taken concurrently with alcohol.


Q: Why is it important to check the official 'Who can and cannot use' list for Hioscina?

Reviewing the contraindications list is crucial because using the medicine with certain pre-existing conditions carries the risk of serious complications. For example, use of the injectable form when contraindicated can risk potentially fatal adverse reactions like anaphylactic shock.


Q: What is the general safety classification of Hioscina according to major health agencies?

Hioscina's injectable form is included on the World Health Organization's Model List of Essential Medicines, which recognizes the drug’s importance in global healthcare. The exact legal status (Prescription-only or Over-the-Counter) of the oral form varies by country based on national regulatory decisions.


Q: What regulatory bodies have approved Hioscina for use?

Hioscina has been approved for use by major regulatory agencies globally, including those in Europe (EMA), the United Kingdom (MHRA), and Canada (Health Canada). This extensive approval history is reflected by its recognition on the WHO Model List of Essential Medicines.


Q: Is Hioscina used in veterinary medicine?

Yes. Official registries indicate that in some countries, such as the United States, the use of Hioscina is restricted to veterinary medicine, specifically for the treatment of horses.

How should Hioscina be stored and disposed of?

How to Store and Dispose of Hioscina (Hyoscine Butylbromide)

The storage and disposal of Hioscina must adhere strictly to government-approved regulatory requirements to maintain product stability and ensure safety.

Storage Conditions

Hioscina tablets should generally be stored below 30°C or at controlled room temperature, although some product labels state no special storage conditions are required. To protect product integrity, the medicine must be protected from light and kept in its original container. All formulations must be stored out of the sight and reach of children.

Disposal Instructions

Any unused or expired medicine and waste material must be disposed of in accordance with local requirements for pharmaceutical products. It is mandated that medicines should not be disposed of via wastewater or household waste to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hioscina found in:

A-Z Index: